Improving pediatric drug efforts
This article was originally published in The Tan Sheet
Executive Summary
FDA will launch an internal panel of experts to provide advice on pediatric studies and exclusivities, Commissioner Andrew von Eschenbach says Oct. 25. With the new Pediatric Review Committee looking over all written requests for pediatric studies, the agency expects to define more precisely the studies it wants industry to perform. The PeRC also will analyze FDA's past performance in implementing provisions of the Pediatric Research Equity Act concerning assessments of a drug's efficacy and safety in the pediatric population. It will be composed of representatives from FDA's centers for drug and for biologics evaluation and research and the commissioner's office and will meet weekly...
You may also be interested in...
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.